The third in a three-part series that explores the multifaceted organizational and strategic decisions that companies are facing as a result of the global AIDS epidemic. Heineken considers to be one of the first companies to offer AIDS drugs (antiretroviral therapy) for employees and their families. Hans Wesseling, corporate HR manager, and his colleagues from the Faculty of Medicine to review the institutional, financial and social consequences of this decision and to make recommendations to the Council. Shows how Heineken in fighting the epidemic and considering it as part of its corporate social responsibility. "Hide
by Diane Barrett, Daniella Ballou Source: Harvard Business School 11 pages. Publication Date: January 27, 2003. Prod. #: 303077-PDF-ENG
Related Case Solutions & Analyses:
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
China Aviation Oil (C): Oil on Troubled Waters
Blue River Capital
Gatewood and Daugherty: Minding Their Own Business
Follow the Insiders or Follow the News: The Case of the Pacific CyberWorks Ltd.
Bell Atlantic and the Union City Schools (C1): Project Explore
Currency Crises
Welch Foods Inc.
Maritime Transportation: The Global System of Shipping and Ports
Two-Column Case Model
